TP53 Comutations, Long-Term Toxicity, and Sunvozertinib Access Shape EGFR+ NSCLC Treatment Decisions
Faculty at an OncLive Scientific Interchange and Workshop discussed factors that help inform treatment selection in advanced EGFR-mutated NSCLC.
|Videos|July 22, 2011
Dr. West Explains the Pemetrexed Clinical Trial
Author(s)H. Jack West, MD
Dr. Jack West from Swedish Cancer Institute Explains the Pemetrexed Clinical Trial
Advertisement
H. Jack West, MD, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington, describes progression free survival (PFS) for patients with advanced nonsquamous non—small cell lung cancer (NSCLC) in the PARAMOUNT phase III trial examining continuation maintenance therapy in two randomized arms; one receiving pemetrexed in addition to best supportive care and the other placebo and best supportive care.
Advertisement
Related to this article
Patrick Forde, MD, MBBCh, details how chemoimmunotherapy, pathologic response, and targeted therapy are reshaping resectable NSCLC care.
The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.
The PCR-based OncoMate MSI Dx Analysis System can now identify patients with MSI-H solid tumors who may be eligible for pembrolizumab.
The FDA set a June 25, 2027, target action date for gedatolisib plus fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.
Pooled phase 1/2 data support 10 mg/kg every 3 weeks as the provisional pivotal dose of the PD-1/VEGF bispecific antibody cesalatamig in previously treated NSCLC.
The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Durvalumab Plus Enfortumab Vedotin for Cisplatin-Ineligible MIBC
2
Dr Gleave on Selecting Patients for Perioperative Therapy in High-Risk Prostate Cancer
3
Dr Calais on Individualizing PSMA-Targeted Therapy Sequencing in Prostate Cancer
4
CHMP Recommends Approval of Belzutifan Plus Lenvatinib for Advanced ccRCC After PD-(L)1 Inhibition
5